Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Moshe Fridman, Mariann E Lucas, Yurek Paprocki, Tam Dang-Tan & Neeraj N Iyer. (2020) Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical Analysis. ClinicoEconomics and Outcomes Research 12, pages 555-566.
Read now
Read now
Thomas Blevins. (2010) Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes. Postgraduate Medicine 122:1, pages 172-183.
Read now
Read now
Peggy Soule Odegard & Anthony DeSantis. (2009) Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 2, pages 135-144.
Read now
Read now
Gisela I Robles & Devada Singh-Franco. (2009) A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Design, Development and Therapy 3, pages 219-240.
Read now
Read now
Stephen Brunton. (2009) Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder. Postgraduate Medicine 121:5, pages 68-81.
Read now
Read now
Joanna Mitri & Osama Hamdy. (2009) Diabetes medications and body weight. Expert Opinion on Drug Safety 8:5, pages 573-584.
Read now
Read now
Articles from other publishers (18)
Qiuhe Ji. (2017) Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. Clinical Therapeutics 39:6, pages 1244-1264.
Crossref
Crossref
Chen Gilor, Adam J Rudinsky & Melanie J Hall. (2016) New Approaches to Feline Diabetes Mellitus. Journal of Feline Medicine and Surgery 18:9, pages 733-743.
Crossref
Crossref
Manjiri Pawaskar, Machaon Bonafede, Barbara Johnson, Robert Fowler, Gregory Lenhart & Byron Hoogwerf. (2013) Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC Endocrine Disorders 13:1.
Crossref
Crossref
Jaime A. Davidson. (2013) Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy 4:2, pages 221-238.
Crossref
Crossref
B. Guerci & J.-P. Sauvanet. (2013) Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?. Médecine des Maladies Métaboliques 7:5, pages 449-463.
Crossref
Crossref
B. T. Blak, H. T. Smith, M. Hards, A. Maguire & V. Gimeno. (2012) A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabetic Medicine 29:8, pages e191-e198.
Crossref
Crossref
Roger S. Mazze, Ellie S. Strock, Richard M. Bergenstal, Amy Criego, Robert Cuddihy, Oded Langer, Gregg D. Simonson & Margaret A. Powers. 2011. Staged Diabetes Management. Staged Diabetes Management
77
137
.
B. Vergès, C. Bonnard & E. Renard. (2011) Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes & Metabolism 37:6, pages 477-488.
Crossref
Crossref
C. Gilor, T.K. Graves, S. Gilor, T.K. Ridge & M. Rick. (2011) The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats. Domestic Animal Endocrinology 41:1, pages 42-49.
Crossref
Crossref
Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez & Abbas E. Kitabchi. (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1, pages 1-23.
Crossref
Crossref
Alfonso López-Ruiz, Cristina Peso-Gilsanz, Amparo Meoro-Avilés, José Soriano-Palao, Alberto Andreu, Juan Cabezuelo & José L. Arias. (2010) Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharmacy World & Science 32:5, pages 559-561.
Crossref
Crossref
Angelos Kyriacou & Abu Baker Ahmed. (2010) Exenatide Use in the Management of Type 2 Diabetes Mellitus. Pharmaceuticals 3:8, pages 2554-2567.
Crossref
Crossref
R. Tirado & A. Caixàs. (2010) Comparativa entre los diversos tratamientos de la hiperglucemia: estrategias para minimizar la ganancia ponderal en la diabetes tipo 2. Avances en Diabetología 26:3, pages 156-160.
Crossref
Crossref
M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay & A. Kilcoyne. (2009) Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism 11:12, pages 1153-1162.
Crossref
Crossref
T. Mittendorf, J. Smith-Palmer, L. Timlin, M. Happich & G. Goodall. (2009) Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 11:11, pages 1068-1079.
Crossref
Crossref
S. L. Norris, N. Lee, S. Thakurta & B. K. S. Chan. (2009) Exenatide efficacy and safety: a systematic review. Diabetic Medicine 26:9, pages 837-846.
Crossref
Crossref
Michael Camilleri. (2009) Peripheral mechanisms in the control of appetite and related experimental therapies in obesity. Regulatory Peptides 156:1-3, pages 24-27.
Crossref
Crossref
J. Philippe & D. Raccah. (2009) Treating type 2 diabetes: how safe are current therapeutic agents?. International Journal of Clinical Practice 63:2, pages 321-332.
Crossref
Crossref